Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Benzinga Newsdesk www.benzinga.com Positive 85.9%

Neg 0% Neu 0% Pos 85.9%

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.